Compare Stocks: TYRA, PTCT, XENE, and DNTH

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DNTH Dianthus Therapeutics	$115.96	$97.47	$19.84 ▼ $116.47	$6.34B	1.22	798,008 shs	903,313 shs
PTCT PTC Therapeutics	$71.70	$77.79	$47.94 ▼ $90.87	$5.98B	0.56	1.21 million shs	564,330 shs
TYRA Tyra Biosciences	$25.29	$29.75	$9.96 ▼ $40.65	$1.51B	0.77	652,009 shs	420,410 shs
XENE Xenon Pharmaceuticals	$62.35	$61.34	$35.60 ▼ $72.66	$6.03B	0.62	622,903 shs	913,582 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DNTH Dianthus Therapeutics	0.00%	+6.46%	+9.81%	+38.71%	+459.11%
PTCT PTC Therapeutics	0.00%	-2.20%	-8.77%	+2.21%	+46.87%
TYRA Tyra Biosciences	0.00%	-4.60%	-21.29%	-29.08%	+135.69%
XENE Xenon Pharmaceuticals	0.00%	-1.59%	-8.66%	+16.09%	+63.09%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DNTH Dianthus Therapeutics	$115.96	$97.47	$19.84 ▼ $116.47	$6.34B	1.22	798,008 shs	903,313 shs
PTCT PTC Therapeutics	$71.70	$77.79	$47.94 ▼ $90.87	$5.98B	0.56	1.21 million shs	564,330 shs
TYRA Tyra Biosciences	$25.29	$29.75	$9.96 ▼ $40.65	$1.51B	0.77	652,009 shs	420,410 shs
XENE Xenon Pharmaceuticals	$62.35	$61.34	$35.60 ▼ $72.66	$6.03B	0.62	622,903 shs	913,582 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DNTH Dianthus Therapeutics	0.00%	+6.46%	+9.81%	+38.71%	+459.11%
PTCT PTC Therapeutics	0.00%	-2.20%	-8.77%	+2.21%	+46.87%
TYRA Tyra Biosciences	0.00%	-4.60%	-21.29%	-29.08%	+135.69%
XENE Xenon Pharmaceuticals	0.00%	-1.59%	-8.66%	+16.09%	+63.09%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DNTH Dianthus Therapeutics	2.93	Moderate Buy	$124.27	7.17% Upside
PTCT PTC Therapeutics	2.64	Moderate Buy	$98.55	37.44% Upside
TYRA Tyra Biosciences	2.87	Moderate Buy	$46.90	85.45% Upside
XENE Xenon Pharmaceuticals	3.00	Buy	$77.13	23.71% Upside

Current Analyst Ratings Breakdown

Latest TYRA, PTCT, XENE, and DNTH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2026	PTCT PTC Therapeutics	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$120.00 ➝ $122.00
8/13/2026	PTCT PTC Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$106.00 ➝ $109.00
8/10/2026	XENE Xenon Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$74.00
8/7/2026	XENE Xenon Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$82.00 ➝ $81.00
8/6/2026	DNTH Dianthus Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$110.00 ➝ $128.00
8/6/2026	DNTH Dianthus Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$130.00 ➝ $158.00
8/6/2026	PTCT PTC Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/5/2026	TYRA Tyra Biosciences	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$42.00
8/5/2026	DNTH Dianthus Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Strong-Buy	$131.00
8/5/2026	DNTH Dianthus Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$105.00 ➝ $122.00
7/31/2026	PTCT PTC Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D) ➝ Sell (D+)

(Data available from 8/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DNTH Dianthus Therapeutics	$2.04M	3,107.61	N/A	N/A	$11.41 per share	10.16
PTCT PTC Therapeutics	$1.01B	5.93	$8.78 per share	8.17	($2.56) per share	-28.01
TYRA Tyra Biosciences	N/A	N/A	N/A	N/A	$4.86 per share	N/A
XENE Xenon Pharmaceuticals	$7.50M	803.65	N/A	N/A	$7.53 per share	8.28

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DNTH Dianthus Therapeutics	-$162.34M	-$4.15	N/A	N/A	N/A	-10,096.95%	-22.53%	-21.55%	11/4/2026 (Estimated)
PTCT PTC Therapeutics	$682.64M	-$0.58	N/A	33.66	2.21	-3.80%	-362.45%	-1.32%	11/3/2026 (Estimated)
TYRA Tyra Biosciences	-$119.95M	-$2.40	N/A	N/A	N/A	N/A	-46.39%	-43.07%	11/4/2026 (Estimated)
XENE Xenon Pharmaceuticals	-$345.91M	-$4.74	N/A	N/A	N/A	N/A	-43.98%	-41.72%	11/2/2026 (Estimated)

Latest TYRA, PTCT, XENE, and DNTH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	XENE Xenon Pharmaceuticals	-$1.16	-$1.11	+$0.05	-$1.11	$1.67 million	N/A
8/4/2026	Q2 2026	DNTH Dianthus Therapeutics	-$0.8463	-$0.90	-$0.0537	-$0.90	$0.30 million	$0.76 million
8/4/2026	Q2 2026	TYRA Tyra Biosciences	-$0.6499	-$0.69	-$0.0401	-$0.69	N/A	N/A
7/30/2026	Q2 2026	PTCT PTC Therapeutics	$0.2363	$0.92	+$0.6837	$0.92	$298.63 million	$360.52 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
DNTH Dianthus Therapeutics	N/A	N/A	N/A	N/A	N/A
PTCT PTC Therapeutics	N/A	N/A	N/A	N/A	N/A
TYRA Tyra Biosciences	N/A	N/A	N/A	N/A	N/A
XENE Xenon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DNTH Dianthus Therapeutics	N/A	26.10	26.10
PTCT PTC Therapeutics	N/A	3.39	3.28
TYRA Tyra Biosciences	N/A	14.90	14.91
XENE Xenon Pharmaceuticals	N/A	21.01	21.02

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DNTH Dianthus Therapeutics	47.53%
PTCT PTC Therapeutics	N/A
TYRA Tyra Biosciences	84.14%
XENE Xenon Pharmaceuticals	95.45%

Insider Ownership

Company	Insider Ownership
DNTH Dianthus Therapeutics	3.02%
PTCT PTC Therapeutics	5.30%
TYRA Tyra Biosciences	12.50%
XENE Xenon Pharmaceuticals	2.91%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DNTH Dianthus Therapeutics	80	54.67 million	53.02 million	Optionable
PTCT PTC Therapeutics	1,410	83.46 million	79.04 million	Optionable
TYRA Tyra Biosciences	20	59.68 million	52.22 million	Optionable
XENE Xenon Pharmaceuticals	210	96.67 million	93.85 million	Optionable

TYRA, PTCT, XENE, and DNTH Headlines

Recent News About These Companies

Walleye Capital LLC Buys New Position in Xenon Pharmaceuticals Inc. $XENE

August 15 at 6:32 AM | marketbeat.com

Steven Gannon Sells 10,000 Shares of Xenon Pharmaceuticals (NASDAQ:XENE) Stock

August 14 at 7:07 AM | insidertrades.com

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Average Rating of "Buy" by Brokerages

August 14 at 2:28 AM | marketbeat.com

Xenon Pharmaceuticals (XENE) Q2 2026 Earnings Call Transcript

August 13, 2026 | finance.yahoo.com

Xenon Pharmaceuticals (NASDAQ:XENE) Director Sells 10,000 Shares of Stock

August 13, 2026 | marketbeat.com

Q3 EPS Forecast for Xenon Pharmaceuticals Boosted by Analyst

August 13, 2026 | americanbankingnews.com

Xenon Pharmaceuticals: Strong Buy On Azetukalner NDA And MDD Expansion Opportunity

August 11, 2026 | seekingalpha.com

HC Wainwright Issues Positive Outlook for XENE Earnings

August 11, 2026 | marketbeat.com

Equities Analysts Set Expectations for XENE Q1 Earnings

August 10, 2026 | americanbankingnews.com

Brokers Issue Forecasts for XENE Q1 Earnings

August 10, 2026 | marketbeat.com

Quantinno Capital Management LP Purchases 30,816 Shares of Xenon Pharmaceuticals Inc. $XENE

August 9, 2026 | marketbeat.com

Xenon anticipates AZK NDA submission later this quarter, while funding operations into 2029

August 7, 2026 | seekingalpha.com

Xenon Pharmaceuticals' Azetukalner NDA Filing Remains on Track After FDA Meeting, RBC Says

August 7, 2026 | finance.yahoo.com

Xenon Pharmaceuticals Q2 Earnings Call Highlights

August 7, 2026 | marketbeat.com

XENE's Q2 Loss Narrower Than Expected, Sales Nil, Pipeline in Focus

August 7, 2026 | zacks.com

California State Teachers Retirement System Buys 36,183 Shares of Xenon Pharmaceuticals Inc. $XENE

August 7, 2026 | marketbeat.com

Xenon Pharmaceuticals Inc. (XENE) Q2 2026 Earnings Call Transcript

August 7, 2026 | seekingalpha.com

Xenon Pharmaceuticals Q2 Loss Widens

August 7, 2026 | finance.yahoo.com

Xenon Pharmaceuticals (NASDAQ:XENE) Announces Quarterly Earnings Results

August 6, 2026 | marketbeat.com

Xenon Reports Q2 2026 Financial Results and Provides Business Update

August 6, 2026 | markets.businessinsider.com

Xenon Pharma Q2 2026 earnings preview

August 6, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TYRA, PTCT, XENE, and DNTH Company Descriptions

Dianthus Therapeutics NASDAQ:DNTH

$115.96 0.00 (0.00%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$118.85 +2.89 (+2.49%)

As of 08/14/2026 07:34 PM Eastern

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

PTC Therapeutics NASDAQ:PTCT

$71.70 0.00 (0.00%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$71.69 -0.01 (-0.01%)

As of 08/14/2026 07:34 PM Eastern

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Tyra Biosciences NASDAQ:TYRA

$25.29 0.00 (0.00%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$24.60 -0.69 (-2.73%)

As of 08/14/2026 07:34 PM Eastern

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.

Xenon Pharmaceuticals NASDAQ:XENE

$62.35 0.00 (0.00%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$62.52 +0.17 (+0.27%)

As of 08/14/2026 07:34 PM Eastern

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TYRA, PTCT, XENE, and DNTH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TYRA, PTCT, XENE, and DNTH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TYRA, PTCT, XENE, and DNTH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TYRA, PTCT, XENE, and DNTH Company Descriptions

Dianthus Therapeutics NASDAQ:DNTH

PTC Therapeutics NASDAQ:PTCT

Tyra Biosciences NASDAQ:TYRA

Xenon Pharmaceuticals NASDAQ:XENE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TYRA, PTCT, XENE, and DNTH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TYRA, PTCT, XENE, and DNTH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TYRA, PTCT, XENE, and DNTH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TYRA, PTCT, XENE, and DNTH Company Descriptions

Dianthus Therapeutics NASDAQ:DNTH

PTC Therapeutics NASDAQ:PTCT

Tyra Biosciences NASDAQ:TYRA

Xenon Pharmaceuticals NASDAQ:XENE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools